Advertisement
News
Advertisement

Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011

Mon, 05/16/2011 - 5:20am
Eli Lilly and Company

INDIANAPOLIS , May 16, 2011 /PRNewswire/ -- Data on nine Lilly Oncology molecules in development will be presented during the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 3 — 7, 2011.  Lilly Oncology's pipeline is one of the largest in the industry, with more than 30 molecules in development to treat various types of cancer.  

Nearly all of these pipeline molecules are being evaluated for certain biomarkers or genetic mutations that can help researchers identify which patients are most likely to respond to these medicines, and as importantly, which are not.  

At ASCO , Lilly will present Phase II data on two fully human IgG1 monoclonal antibodies: cixutumumab for the treatment of patients with advanced or metastatic soft tissue sarcoma and Ewing family of tumors; and ramucirumab for the treatment of locally advanced or metastatic breast cancer.  Lilly will also present data on a Phase I study of LY2127399, a human anti-BAFF antibody for patients with previously-treated multiple myeloma.  Additionally, Lilly will present data from several studies of enzastaurin, a selective serine-threonine kinase inhibitor that targets the PKC Beta and PI3/AKT pathways.

"Lilly is very much in alignment with this year's ASCO conference theme, 'Patients, Pathways, Progress,'" said Richard Gaynor , M.D., vice president, product development and medical affairs for Lilly Oncology.  "Our extensive oncology pipeline targets important pathways and specific genetic mutations that can lead to cancer, which we hope will enable us to come up with better therapies, more quickly.  This is part of our commitment to changing the world of cancer care," he added.    

Select studies, as well as the times and locations of the data sessions, are highlighted below.

Cixutumumab (IMC-A12)

  • Abstract # 10004: Oral Abstract Session: Monday, June 6, 2011 , 4:15 PM - 4:30 PM
    • Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft tissue sarcoma and Ewing family of tumors.
    • Author/Speaker: P. Schoffski, D. Adkins , J. Y. Blay , T. Gil, A. D. Elias , P. Rutkowski , G. K. Pennock , H. Youssoufian , N. J. Zojwalla, R. Willey , D. O. Grebennik
    • Location: E354a

Ramucirumab (IMC-1121B)

  • Abstract #TPS151: Trials in Progress Poster Session: Monday, June 6, 2011 , 8:00 AM - 12:00 PM
    • Randomized phase 2 study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402).
    • Author/Speaker: L. T. Vahdat , K. Miller , J. A. Sparano , H. Youssoufian , J. D. Schwartz, S. Nanda, W. Wang, L. Abad , A. Dontabhaktuni, M. D. Rutstein
    • Location: Hall A; Poster Board 42E

Anti-BAFF antibody (LY2127399)

  • Abstract #8012: Oral Abstract Session: Sunday, June 5, 2011 , 11:15 AM - 11:30 AM
    • Phase 1 study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously-treated multiple myeloma
    • Author/Speaker: Noopur Raje , Raymond Hohl , Edward Faber , Paul Richardson , Andres Forero , Gary Schiller , Adam Cohen , Susan Carpenter , Damien Cronier , Maksim Pashkevich , James Wooldridge , Kenneth Anderson
    • Location: E354a

Enzastaurin

  • Abstract # 8016: Poster Discussion Session: Saturday, June 4, 2011 , 8:00 AM - 12:00 PM
    • Randomized Phase II Study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate and high-risk diffuse large B-cell lymphoma (DLBCL) — Preliminary Analysis
    • Author/Speaker: John D. Hainsworth , Edward R. Arrowsmith , Michael McCleod , Luis E. Fayad , Oday Hamid , Lori Davis , Boris Lin
    • Location: E450b; Poster Board: 2
  • Abstract # 1507: Oral Abstract Session: Monday, June 6, 2011 , 5:15 PM - 5:30 PM
    • Final Results of a Chemoprevention Trial with Enzastaurin in Former Smokers
    • Author/Speaker: J. Gray , S. Altiok, M. Alexandrow , F. Walsh , J. Chen , D. Tai , G. Bepler
    • Location: S100bc

TGF-beta molecule (LY2157299)

  • Abstract # 3011: Poster Discussion Session: Saturday, June 4, 2011 , 2:00 PM - 6:00 PM
    • First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.
    • Author/Speaker: Jordi Rodon Ahnert
    • Location: S403; Poster Board #1

P-LLY

This press release contains forward-looking statements about the potential of cixutumumab, ramucirumab, enzastaurin, LY2127399 and LY2157299 and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the products will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission . Lilly undertakes no duty to update forward-looking statements.

(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading